LLY Stock Outlook 2026: Eli Lilly's GLP-1 Empire Hits Growing Pains
Eli Lilly (LLY) 2026 analysis covering the GLP-1 franchise (Zepbound/Mounjaro), manufacturing capacity bottleneck, compounded semaglutide litigation, and what donanemab and orforglipron mean for the next growth chapter.
LLY Eli Lilly GLP-1